AlphaMadera's AlphaVal page classifies ARS Pharmaceuticals, Inc. as a High-Growth Software business and values it using Revenue × Terminal Margin DCF, then compares the result to the current market price to flag SPRY as undervalued, fairly valued, or overvalued.

What is ARS Pharmaceuticals, Inc.'s fair value?

Fair value for SPRY comes from a Revenue × Terminal Margin DCF model -- the approach AlphaVal selected for this company's High-Growth Software classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value SPRY?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. SPRY was classified as High-Growth Software and is valued using Revenue × Terminal Margin DCF, built from SPRY's most recent reported fundamentals.

SPRY - ARS Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $25.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

High-Growth Software 80% confidence

Primary model: Revenue × Terminal Margin DCF

Valuation Signal Undervalued Moderate

Trading 25.8% below fair value

Current Price $6.00

Bear Case $3.93 34.4% downside ($3.93 - $6.00) / $6.00 = -34.4% 18% rev growth, 17% terminal margin

Fair Value $8.09 34.8% upside ($8.09 - $6.00) / $6.00 = 34.8% 30% rev growth, 23% terminal margin

Bull Case $11.43 90.6% upside ($11.43 - $6.00) / $6.00 = 90.6% 35% rev growth, 26% terminal margin

Adjust Assumptions

Revenue Growth Rate

30.0%

Terminal FCF Margin

23.0%

Discount Rate

12.0%

Key Value Driver

Revenue growth (30%) × margin expansion to 23%

Terminal Value % of EV 69%

Implied Market Multiple 5.3x

Market is pricing in (growth)

Plain-Language Summary

Projecting 30% revenue growth with FCF margins expanding from 0% to 23% over 10 years, discounted at 12%, the base-case value is $8.09 per share.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (10 analysts) $25.50

Analyst Range $25.00 – $26.00

Divergence from AlphaVal 68%

Warnings

⚠ Stock-based employee pay is 26% of revenue — your ownership shrinks by about 2.0% each year as new shares are issued. Our estimate already accounts for this dilution.

⚠ Our estimate assumes profit margins grow from 0% to 23% over 10 years. If that improvement stalls, the company is worth considerably less.

ℹ Gross margin of 76% means each dollar of revenue is highly profitable. As the company grows, overhead costs should shrink as a share of revenue, boosting overall profits.

ℹ Wall Street's average price target is $25.50 (from 10 analysts). Our estimate is 68% below the consensus -- consider that gap carefully.

⚠ This stock is 54% below its 52-week high, with weak or declining earnings. That combination often signals real trouble, even though the valuation below is based on other fundamentals.

Key Risks

Current FCF misleads — the model values future margins, not today's cash
SBC dilution is the hidden tax: 2-4% annual share growth compounds fast
Revenue deceleration is inevitable — the question is when and how steep